Form 4: Cabaletta Bio CFO Anup Marda Granted Stock Options

Anup Marda, CFO of Cabaletta Bio, Inc., was granted stock options for 145,000 shares on March 3, 2025.

Summary

• Anup Marda, the Chief Financial Officer of Cabaletta Bio, Inc. (CABA), was granted stock options on March 3, 2025.
• The stock options give Marda the right to buy 145,000 shares of Cabaletta Bio's common stock at an exercise price of $1.67 per share.
• 25% of the options will vest on March 3, 2026, and the remaining options will vest in twelve equal quarterly installments thereafter, contingent upon Marda's continued service.
• The options expire on March 2, 2035.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants. It is neutral in tone and does not contain any information that would significantly impact investor sentiment.

Positives

• The granting of stock options to the CFO aligns their interests with those of the shareholders, incentivizing them to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key executives. They align management's interests with those of shareholders by incentivizing them to increase the company's stock price.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The stock option grant could potentially benefit shareholders if the CFO's performance leads to an increase in the company's stock price.
• The grant incentivizes the CFO to remain with the company and contribute to its long-term success.

Key Dates